Not all evidence is built the same.
People here are treating this low tier evidence the same as a proper RCT.
Theres a reason that's not how it works in the scientific community.
If you ever had to critique and discuss peer reviewed articles you would know even well designed RCTs with low p values have issues that need serious consideration.
Im simply not swayed by a company that consistently failed its trials, but then goes back, trawls through sub groups until it finds some significance, and then pushes it as a success. It's not a success, it has created another hypothesis that needs to be confirmed. That's it
Not all evidence is built the same.People here are treating this...
-
- There are more pages in this discussion • 383 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.16 |
Change
0.005(0.43%) |
Mkt cap ! $1.318B | |||
| Open | High | Low | Value | Volume |
| $1.15 | $1.17 | $1.13 | $3.743M | 3.261M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 78561 | $1.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.16 | 114667 | 4 |
View Market Depth
| Last trade - 16.10pm 22/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |